Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

68 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2023.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 52,233,706 shares of 121,543,157 outstanding shares and own 43% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11,370,376 shares), Frazier Life Sciences Management, L.P. (7,381,090 shares), Rubric Capital Management LP (5,684,420 shares), VIKING GLOBAL INVESTORS LP (4,400,000 shares), VR Adviser, LLC (3,422,397 shares), Opaleye Management Inc. (2,535,000 shares), BlackRock Inc. (2,319,715 shares), VANGUARD GROUP INC (2,243,399 shares), Rosalind Advisors, Inc. (1,862,425 shares), and Checkpoint Capital L.P. (1,292,316 shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.